JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug
Jazz Pharmaceuticals strikes a $1B licensing deal with Saniona for SAN2355, an epilepsy drug designed to target seizure control more precisely.
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, Aug. 19, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ( Nasdaq: ZYME ) , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, ...
Zymeworks Announces Participation in Upcoming Investor Conferences - Zymeworks ( NASDAQ:ZYME )
VANCOUVER, British Columbia, Aug. 19, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc.
Onco360 adds Modeyso™ ( dordaviprone ) to portfolio of Oncology and Rare Cancer therapies as a National Specialty Pharmacy Provider
LOUISVILLE, Ky., Aug. 13, 2025 ( GLOBE NEWSWIRE ) -- Onco360®, the nation's leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Jazz Pharmaceuticals for Modeyso™ ( dordaviprone ) .
Artios Pharma Appoints Michael T. Andriole as CEO and Director to Advance Alnodesertib ( ART0380 ) into Late-stage Development
Mike Andriole brings approximately 25 years of experience in the biopharmaceutical industry and a successful track record of delivering new first-in-class oncology therapies in indications of high unmet need to patients where no approved treatment exists
Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry
VANCOUVER, British Columbia, Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ( Nasdaq: ZYME ) , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, ...
Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry - Zymeworks ( NASDAQ:ZYME )
VANCOUVER, British Columbia, Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc.
Don't Overlook Jazz ( JAZZ ) International Revenue Trends While Assessing the Stock
Evaluate Jazz's (JAZZ) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Jazz ( JAZZ ) Q2 Revenue Rises 2%
Jazz Pharmaceuticals ( NASDAQ:JAZZ ) is a global biopharmaceutical company focused on innovative therapies for neuroscience and rare oncology diseases. On August 5, 2025, it reported second quarter results for fiscal 2025.
JAZZ Stock Down on Wider-Than-Expected Q2 Loss, '25 Sales View Cut
Jazz shares slide as Q2 loss widens on Chimerix charge, with 2025 sales outlook trimmed despite higher EPS guidance.
Jazz Pharmaceuticals ( JAZZ ) Reports Q2 Loss, Misses Revenue Estimates
Jazz (JAZZ) delivered earnings and revenue surprises of -34.80% and -0.26%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
AXSM Q2 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y
Axsome posts narrower second-quarter loss and 72% revenue surge, driven by strong Auvelity sales.
Sarepta Therapeutics ( SRPT ) to Report Q2 Results: Wall Street Expects Earnings Growth
Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Jazz Pharmaceuticals ( JAZZ ) Q2 Earnings Expected to Decline
Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate
VANCOUVER, British Columbia, July 28, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ( Nasdaq: ZYME ) , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, ...
2 Top Stocks I Wouldn't Hesitate to Invest $1,000 in Right Now
Should you invest in stocks right now? Some might be hesitant to do so because of the volatility broader equities have faced this year. Others understand that the stock market generates excellent returns over the long run, regardless of short-term uncertainty.I firmly belong to the second camp.
Strength Seen in ABCELLERA BIOLG ( ABCL ) : Can Its 15.0% Jump Turn into More Strength?
ABCELLERA BIOLG (ABCL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
ALKS Down Despite Positive Top-Line Data From Narcolepsy Study
Alkermes falls 8.8% despite alixorexton hitting key goals in a narcolepsy type 1 study, as cataplexy data stirs investor concerns.
Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025
Company to participate in investor conferences in July and August Company to participate in investor conferences in July and August ...
Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025 - Zymeworks ( NASDAQ:ZYME )
VANCOUVER, British Columbia, July 17, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc.
HYTN Secures Cannabis Drug Licence, Advancing Prescription Drug Pathway for Cannabinoid-Based Medicines - HYTN Innovations ( OTC:HYTNF )
VANCOUVER, British Columbia, July 14, 2025 ( GLOBE NEWSWIRE ) -- HYTN Innovations Inc. HYTN FSE: 85W0,HYTNF ( "HYTN" or the "Company" ) , a leader in pharmaceutical-grade cannabis manufacturing, is pleased to announce it has received a Cannabis Drug Licence ( CDL ) from Health Canada.
Here's Why Harmony Biosciences Is an Unconventional Cannabis Investment
HRMY isn't your typical cannabis play - its synthetic CBD gel targets rare brain disorders with no approved therapies.
Avadel Shareholder Seeks Board Shakeup, Citing Millions Lost On Lumryz - Avadel Pharmaceuticals ( NASDAQ:AVDL )
ASL estimates Avadel missed $600 million-$800 million in revenue by delaying Lumryz patient conversion. The company's market cap dropped from $2.5 billion to $900 million as CEO compensation reached $7.4 million. Market-moving news hits Benzinga Pro first-get a 30-minute edge and save 60% this ...
Avadel Pharmaceuticals Announces Unanimous Appeals Court Decision Upholding FDA Approval of LUMRYZ in Narcolepsy in Administrative Procedure Act Litigation
DUBLIN, June 30, 2025 ( GLOBE NEWSWIRE ) -- Avadel Pharmaceuticals plc ( Nasdaq: AVDL ) , a biopharmaceutical company focused on transforming medicines to transform lives, announced that, on Friday, June 27, 2025, the U.S. Court of Appeals for the District of Columbia Circuit ( the "Appeals ...
Avadel Pharmaceuticals Announces Unanimous Appeals Court Decision Upholding FDA Approval of LUMRYZ in Narcolepsy in Administrative Procedure Act Litigation - Avadel Pharmaceuticals ( NASDAQ:AVDL )
DUBLIN, June 30, 2025 ( GLOBE NEWSWIRE ) -- Avadel Pharmaceuticals plc AVDL, a biopharmaceutical company focused on transforming medicines to transform lives, announced that, on Friday, June 27, 2025, the U.S. Court of Appeals for the District of Columbia Circuit ( the "Appeals Court" ) affirmed ...
Xenon Announces Appointment of Darren Cline as Chief Commercial Officer
Mr. Cline brings extensive commercial expertise to lead the transition of Xenon to a commercial-stage company with the anticipated launch of azetukalner across three potential indications Mr. Cline brings extensive commercial expertise to lead the transition of Xenon to a commercial-stage ...
Why Is Jazz ( JAZZ ) Up 7.9% Since Last Earnings Report?
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
2 Soaring Stocks Wth More Upside Potential
Although fundamental investing wisdom tells us to "buy low," it may still be worthwhile to purchase shares of top companies following significant runs. Any point can be considered low -- even after massive gains -- provided there is plenty of upside left.
Jazz Pharma's Zepzelca Combo Shows Survival Edge In Lung Cancer Study - Jazz Pharmaceuticals ( NASDAQ:JAZZ )
Zepzelca combo cuts the risk of disease progression or death by 46% and death by 27% vs. Tecentriq alone. Median PFS was 5.4 months with combo vs. 2.1 months with Tecentriq; OS was 13.2 vs. 10.6 months. Ready to turn the market's comeback into steady cash flow? Grab the top 3 stocks to buy right ...
Roche's Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer
Basel, 3 June 2025 - Roche ( SIX: RO, ROG. OTCQX: RHHBY ) announced today positive results from the Phase III IMforte study of Tecentriq® ( atezolizumab ) in combination with lurbinectedin ( Zepzelca® ) as a first-line maintenance treatment for people with extensive-stage small cell lung cancer ( ...
Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression ( IHC3+ ) Biliary Tract Cancer
VANCOUVER, British Columbia, May 30, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ( Nasdaq: ZYME ) , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, ...
Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression ( IHC3+ ) Biliary Tract Cancer - Zymeworks ( NASDAQ:ZYME )
Zanidatamab is the first and only dual HER2-targeted bispecific antibody approved for HER2+ biliary tract cancer in China; conditional approval based on the results of the HERIZON-BTC-01 clinical study $20 million milestone payment to be received from BeOne Medicines.
Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences - Zymeworks ( NASDAQ:ZYME )
Partner presentations reinforce ability of proprietary Azymetric™ platform to develop clinically validated therapeutic antibodies
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, May 21, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ( Nasdaq: ZYME ) , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, ...
Zymeworks Announces Participation in Upcoming Investor Conferences - Zymeworks ( NASDAQ:ZYME )
VANCOUVER, British Columbia, May 21, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc.
Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference
VANCOUVER, British Columbia, May 19, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ( Nasdaq: ZYME ) , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, ...
Major Purchase Alert: Seamus Mulligan Invests $9.99M In Jazz Pharmaceuticals Stock - Jazz Pharmaceuticals ( NASDAQ:JAZZ )
In a recent SEC filing, it was revealed that Seamus Mulligan, Board Member at Jazz Pharmaceuticals JAZZ, made a noteworthy insider purchase on May 13,. What Happened: A Form 4 filing with the U.S.
Unlocking Jazz ( JAZZ ) International Revenues: Trends, Surprises, and Prospects
Evaluate Jazz's (JAZZ) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Pharma Stock Roundup: NVO & JAZZ's Q1 Results, AZN's Pipeline Update
NVO and JAZZ report first-quarter results. AZN's asthma study on Breztri meets key goals.
Cannabis Stock Tilray Brands Loses 19% in a Month: Time to Sell or Hold?
TLRY's pivot into beverages shows promise, but with falling cannabis sales and delisting risks, we recommend staying on the sidelines for now.
JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook
Jazz reports dismal first-quarter results. The company revises its 2025 EPS guidance to account for the recently completed Chimerix acquisition.
Jazz Pharmaceuticals ( JAZZ ) Q1 Earnings and Revenues Lag Estimates
Jazz (JAZZ) delivered earnings and revenue surprises of -62.75% and 8.52%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Avadel Pharmaceuticals Announces Favorable Ruling in Appeal of Delaware Court Injunction
- With this ruling, Avadel can seek and be granted FDA approval for LUMRYZ in Idiopathic Hypersomnia ...
AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y
Axsome reports better-than-expected first quarter 2025 results. Net product revenues surge year over year on strong Auvelity sales.
Illumina ( ILMN ) Earnings Expected to Grow: Should You Buy?
Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Buy, Sell or Hold JAZZ Stock? Key Tips Ahead of Q1 Earnings
Investors will likely focus on the sales performance of Jazz Pharmaceuticals' key neuroscience drugs, Xywav and Rylaze, when it reports Q1 results next week.
Jazz Pharmaceuticals ( JAZZ ) Earnings Expected to Grow: Should You Buy?
Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Unconventional Cannabis Stocks to Watch in 2025
Think cannabis investing is all hype? These three unconventional stocks could change your mind - and your portfolio - in 2025.
Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting
Six posters highlight continued progress across antibody-drug conjugate and T cell engager platforms ...
Buy 5 High ROE Stocks as Markets Break Tariff-Induced Losing Streak
CBOE, AGNC, JAZZ, AES and CNSWF are some of the stocks with high ROE to profit from as markets expect the tariff war to end soon.
